干扰素-阿尔法降低癌症干细胞的特性,并调节恶性黑色素瘤中的外体
María Belén García-Ortega1,2,3,4, Ernesto Aparicio1,2,3,5, Carmen Griñán-Lisón1,2,3,6,7
1Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, University of Granada, 18016 Granada, Spain.
低剂量的干扰素-α (IFN-α) 有效地降低了黑色素瘤癌干细胞 (CSC) 和它们的瘤形成能力. 这种方法与代谢生物标志物分析相结合,为对抗侵袭性黑色素瘤提供了潜在的策略.
科学领域:
- 在瘤学瘤学.
- 癌症干细胞生物学
- 免疫治疗是一种免疫疗法.
背景情况:
- 恶性黑色素瘤 (MM) 由于癌症干细胞 (CSC) 亚群表现出耐药性.
- 高剂量干扰素α (IFN-α) 用于黑色素瘤,但具有显著的副作用.
研究的目的:
- 评估低剂量和高剂量的IFN-α对黑色素瘤CSCs的影响.
- 评估IFN-α对CSC干,迁移和瘤启动的影响.
- 调查由IFN-α引起的基因组和外体变化.
主要方法:
- 对CSC标记物的分析 (ALDH活性,侧面人群,表面标记物).
- 在体外和体内对克隆性,迁移和瘤启动的评估.
- 基因组分析 (microRNA测序,微阵列) 和外体特征 (NanoSight,LC-HRMS代谢学).
主要成果:
- 低剂量和高剂量的IFN-α都减少了CSC的形成和茎状性质.
- 在异种移植小鼠中,IFN-α显著降低了瘤启动能力.
- IFN-α调节的基因/microRNA表达和外体代谢,影响癌症过程.
结论:
- 低剂量的IFN-α显示对黑色素瘤CSC的有效性,降低了它们的攻击性和瘤形成潜力.
- IFN-α 影响关键的癌症通路和外体细胞沟通.
- 将低剂量IFN-α与代谢生物标志物分析相结合,可能为黑色素瘤治疗提供一种新的临床策略.
更多相关视频
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
12:16Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
相关概念视频
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Mesenchymal Stem Cells
Regulation of Hematopoietic Stem Cells
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Induced Pluripotent Stem Cells
Somatic...
Tumor Immunotherapy
